Predicting drug interactions and pharmacokinetic variability with in vitro methods: The olanzapine experience

Drug Metabolism Reviews

Volumn 31, Issue 1, 1999, Pages 15-28

  Wrighton, Steven A ^a   Ring, Barbara J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYMETHYLOLANZAPINE; 7 HYDROXYOLANZAPINE; CLOZAPINE; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; DRUG METABOLITE; N NOROLANZAPINE; N OXIDYLOLANZAPINE; OLANZAPINE; PHENACETIN O DEETHYLASE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG INTERACTION; DRUG METABOLISM; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; PHARMACOKINETICS; PREDICTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MICROSOMES, LIVER; PIRENZEPINE;

EID: 0033005086     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-100101905     Document Type: Conference Paper

References (13)

1. D. R. Nelson, L. Koymans, T. Kamataki, J. J. Stegeman, R. Feyereisen, D. J. Waxman, M. R. Waterman, O. Gotoh, M. J. Coon, R. W. Estabrook, I. C. Gunsalus, and D. W. Neben, Pharmacogenesis, 6, l (1996).
2. S. A. Wrighton and J. C. Stevens, Crit. Rev. Toxicol, 22, l (1992).
3. F. P. Guengerich, in Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd ed. (P. Ortiz de Montellano, ed.), Plenum Press, New York, 1995, pp. 473-535.
4. S. Rendic and F. J. Di Carlo, Dmg Metab. Rev., 29, 413 (1997).
5. T. Shimada, H. Yanazaki, M. Minura, Y. Inui, and F. P. Guengerich, J. Pharmacol. Exp. Ther., 270, 414 (1994).
6. B. J. Ring, S. N. Binkley, M. VandenBranden, and S. A. Wrighton, Br. J. Clin. Pharmacol., 41, 1881 (1996).
7. B. J. Ring, J. Catlow, T. J. Lindsay, T. Gillespie, L. K. Roskos, B. J. Cerimele, S. P. Swanson, M. A. Hamman, and S. A. Wrighton, J. Pharmacol. Exp. Ther., 276, 658 (1996).
8. K. Kassahum, E. Mattiuz, E. Nyhart, B. Öbermeyer, T. Gillespie, A. Murphy, R. M. Goodwin, D. Tupper, J. T. Callaghan, and L. Lemberger, Drug Metab. Disp., 25, 81 (1997).
9. J. R. Cashman, S. B. Park, Z. C. Yang, S. A. Wrighton, P. Jacob, and N. L. Beneowitz, Chem. Res. Toxicol., 5, 639 (1992).
10. M. V. Relling, J. S. Lin, G. D. Ayers, and W. E. Evans, Clin. Pharmacol. Ther., 52, 643 (1992).
11. L. Ereshefsky, J. Clin. Psychiatry, 57, 12 (1996).
12. Eli Lilly and Company, New Drug Application no. 20-592 (1996).
13. J. Maenpaa, S. A. Wrighton, R. Bergstrom, B. Cerimele, D. Tatum, B. Gathcher, and J. T. Callaghan, Clin. Pharmacol. Ther., 61, 225 (1997).